Enfortumab vedotin, a NECTIN4-targeting antibody-drug conjugate (ADC), is in clinical use for urothelial cancer. Using patient specimens and preclinical models, Wang et al. identify an endocytic trafficking defect that limits ADC uptake and efficacy and propose a strategy to overcome this resistance. This trafficking-based mechanism may also underlie resistance to other ADCs in the clinic.
